Special Issue

microRNA and Oxidative Drugs in Cancer Therapy and Prevention

Message from the Guest Editors

The epigenetic control of gene expression is achieved at the postgenomic level in the cytoplasm by microRNA machinery. MicroRNAs are able to intercept and suppress messenger RNAs encoded by mutated oncogenes, thus blocking the progress, spreading, and recurrences of cancer. Indeed, cancer growth occurs only when microRNA machinery is severely damaged. MicroRNA expression can be restored and modulated by the administration of suitable microRNA mimics..... The goal of this Special Issue is to focus on the clinical applicability of microRNA and oxidative drugs to cancer therapy and prevention. The issue will analyze the status of experimental knowledge in preclinical experimental models as well as the translatability of the obtained results to the clinics. Attention will be focused on the use of microRNA and oxidative drugs as complimentary approaches to chemo-radiotherapies in cancer therapy to overcome resistance and in cancer prevention to decrease the risk of relapses.

Guest Editors

Prof. Dr. Alberto Izzotti

Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy

Prof. Dr. Ming You

Center for Disease Prevention Research and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Deadline for manuscript submissions

closed (31 March 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/76045

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)